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ABSTRACT
Objective: Whether reducing low density lipoprotein cholesterol (LDL-C) is associated with cardiovas-
cular benefits in low risk normocholesterolaemic subjects is unknown. The INTENSITY LOW
[Investigating the lowest threshold of vascular benefits from LDL-cholesterol lowering with a PCSK9
mAb inhibitor (alirocumab) in healthy volunteers] study aims to assess whether lowering LDL-C by alir-
ocumab monotherapy can improve endothelial-dependent vascular function compared with placebo
(primary objective) in low-risk normocholesterolaemic healthy individuals. Changes in endothelial-
dependent or endothelial-independent vascular function, arterial stiffness and biomarkers of systemic
inflammation by alirocumab, atorvastatin or their combination are secondary objectives.
Study design and methods: This is a single-center, randomized, two-period, single-blind, placebo-
controlled clinical trial. The study was registered on clinicaltrials.gov (N03273972).
It will include 30 healthy low-risk subjects with LDL-C< 4.1mmol/l. After passing the screening visit
(Visit 1), eligible participants will be randomized 1:1 to either subcutaneous alirocumab 150mg or pla-
cebo. These will be administered as single doses in 2 visits 14 days apart (Visits 2 and 3). Atorvastatin
20mg once nightly will be prescribed for 14 days at Visit 3 in both groups through to Visit 4.
At baseline (Visit 2) and during all post-dose visits (Visits 3–4), endothelial function will be assessed
using venous occlusion plethysmography. Specifically, changes in forearm blood flow responses to
intra-arterial infusions of acetylcholine, sodium nitroprusside and L-NG-monomethyl-arginine acetate
will be assessed as surrogates of endothelial-dependent and -independent vasodilatation. Additionally,
arterial stiffness and carotid intima-media thickness will be evaluated at the same timepoints. The
above-mentioned changes will be correlated with changes in lipid and systemic inflamma-
tion biomarkers.
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Introduction – rationale of the study
Cardiovascular (CV) disease remains the commonest cause of
mortality worldwide. Hypercholesterolemia, particularly ele-
vated low-density lipoprotein cholesterol (LDL-C), is consid-
ered an independent CV risk factor1. Statins are first-line
evidence-based medications to significantly lower LDL-C
levels and CV events in both the primary and secondary pre-
vention setting2. Despite effective LDL-C lowering, a consid-
erable residual CV risk still exists.
Endothelial dysfunction presents early in the atheroscler-
otic process and contributes to this residual risk3. There is a
cross-talk between hypercholesterolemia, low-grade vascular
inflammation, oxidative stress and endothelial dysfunction4,5.
Namely, the accumulation of LDL particles in the
subendothelial space and their oxidative modification
(oxLDL) alongside the oxidation of the lipoprotein-associated
phospholipids results in vascular inflammation. It also results
in impaired endothelial-dependent vasodilatation through
reduced nitric oxide (NO) bioavailability6.
The gold standard for assessing endothelial function is
measuring forearm blood flow using venous occlusion ple-
thysmography7. This is a well described method of assessing
and determining vascular function, which can interrogate
endothelial NO dependent and independent mechanisms8.
It can also predict the risk of future CV events9. Arterial stiff-
ness is now rapidly being accepted as a global measure of
functional and structural changes, which accompanies CV
disease and is associated with outcomes10.
CONTACT Michael S. Kostapanos mk828@medschl.cam.ac.uk Division of Experimental Medicine and Immunotherapeutics, and Addenbrooke’s Hospital,
Cambridge University Hospitals NHS Foundation Trust, Box 98, Level 3 Addenbrooke’s Centre for Clinical Investigations, Cambridge, CB2 0QQ, UKThese authors equally contributed to this work.
 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits
unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
www.tandfonline.com/ijda
JOURNAL OF DRUG ASSESSMENT
2019, VOL. 8, NO. 1, 167–174
https://doi.org/10.1080/21556660.2019.1677673
Article 0013.R1/1677673
It is now apparent that lowering LDL-C levels is the main
lipid change to result in significant outcome benefits. In this
context, statin-related CV risk reduction has been propor-
tional to their LDL-C lowering effects in both the primary and
secondary prevention2. However, it has also been proposed
that these benefits are related to properties beyond lipid-low-
ering (the so-called pleiotropic effects). These include anti-oxi-
dant and anti-inflammatory actions as well as atherosclerotic
plaque stabilization11. Statins also improve NO bioavailability,
and subsequently endothelial function11. Nevertheless, it has
been debated whether the latter is a lipid-dependent or
indeed a pleiotropic effect of statins per se. In this regard,
similar LDL-C reductions by either statins or non-statin lipid
lowering medications resulted in comparable endothelial
function improvement and arterial stiffness reduction12.
Accumulating evidence suggests that boosting LDL-C lower-
ing by adding either ezetimibe or proprotein convertase subti-
lisin kexin type 9 (PCSK9) inhibitors to statins is associated
with greater benefits in CV morbidity and mortality. This was
evident even in patients with mildly raised LDL-C levels at
baseline13–15. PCSK9 inhibitors (e.g. alirocumab and evolocu-
mab) are very potent lipid lowering medications exhibiting
effects at least comparable to statins on LDL-C, when used as
monotherapy16. The synergistic effects on LDL-C lowering
when combined with statins resulted in very low on-treatment
levels, especially in secondary prevention trials14, 15. These lev-
els had not been previously encountered in statin ±ezetimibe
trials and were associated with further reductions in CV mor-
bidity and mortality13–15. To date, the threshold of LDL-C
below which no further CV benefit is expected has not been
yet identified in secondary prevention trials17.
In the primary prevention setting, such evidence is even
poorer, since hard outcome clinical trials with PCSK9 inhibitors
or ezetimibe combined with statins are lacking. It has been
widely shown that statin benefits are more apparent in inter-
mediate and high-risk hypercholesterolaemic individuals, while
only modest in low-risk ones2. Also, statin benefits on hard
outcomes may extend to intermediate- and high-risk normo-
cholesterolaemic populations with subclinical levels of inflam-
mation18, 19. This evidence suggests that some extra benefit
from LDL-C lowering is expected even within the normal
range. However, the LDL-C threshold below which no more
benefit is expected in primary prevention remains unknown17.
There is a paucity of data on whether reducing LDL-C can
result in CV risk reduction in low-risk normocholesterolaemic
individuals. The INTENSITY LOW study (Investigating the lowest
Threshold of vascular benefits from LDL-cholesterol lowering
with a PCSK9 mAb inhibitor (alirocumab) in healthy volunteers
– A mechanistic physiological study) seeks to answer if there
are limits to LDL-C reduction in terms of benefits to vascular
health from a mechanistic viewpoint. It also evaluates whether
there are potential limitations to primary prevention in healthy
volunteers by lowering LDL-C using PCSK9 inhibitors. This will
determine if there is a plateau beyond which there is no fur-
ther benefit on early biomarkers of CV disease.
We suggest that identifying this threshold will have major
public health implications, by changing the conception of
what is ‘normal cholesterol’. The INTENSITY-LOW study will
also investigate whether LDL-C lowering via PCSK9 inhibition
has comparable benefits in vascular function to the ones
achieved by statins. This will provide significant and specific
evidence that the so-called pleiotropic effects of statins are
mediated by LDL-C lowering per se, and not necessarily by
extra-lipid actions.
Study objectives
The primary objective of the study is to assess whether LDL-C
reduction with alirocumab improves NO bioavailability as
measured by forearm plethysmography in healthy normo-
cholesterolaemic individuals. Assessment of whether: (1) alir-
ocumab is comparable to statin in improving endothelial
function when similar LDL-C lowering is achieved; (2) alirocu-
mabþ statin is better than statin monotherapy in improving
endothelial function, due to more potent LDL-C lowering
with the combination therapy; (3) alirocumab reduces
markers of systemic inflammation in healthy individuals; (4)
to provide inputs to a decision model to explore whether
alirocumab has the potential to be cost-effective in healthy
individuals.
Study outcome measures
The primary outcome measure for the study is the change in
forearm blood flow ratio (and additionally, absolute and %
change), as measured by venous occlusion plethysmography,
in response to intra-arterial Acetylcholine (ACh) infusion,
comparing alirocumab with placebo. Secondary outcome
measures include change in forearm blood flow ratio com-
paring various treatment groups, as well as change in arterial
stiffness and other haemodynamic measurements. These are
detailed in Textbox 1.
Textbox 1. Study outcome measures.
Primary outcome measure
1. Change in forearm blood flow ratio (additionally absolute and %
change, based on data), as measured by venous occlusion
plethysmography, in response to intra-arterial acetylcholine (Ach)
infusion, comparing alirocumab with placebo.
Secondary outcome measures
1. Change in forearm blood flow ratio (additionally absolute and
% change, based on data), as measured by venous occlusion
plethysmography, in response to intra-arterial Ach infusion,
comparing alirocumab with statin.
2. Change in forearm blood flow ratio (additionally absolute and
% change, based on data), as measured by venous occlusion
plethysmography, in response to intra-arterial Ach infusion,
comparing alirocumab with statin versus statin alone.
3. Change in forearm blood flow ratio (additionally absolute and
% change, based on data), as measured by venous occlusion
plethysmography, in response to intra-arterial sodium
nitroprusside (SNP), comparing alirocumab with placebo.
4. Change in forearm blood flow ratio (additionally absolute and
% change, based on data), as measured by venous occlusion
plethysmography, in response to intra-arterial SNP, comparing
alirocumab with statin.
5. Change in forearm blood flow ratio (additionally absolute and
% change, based on data), as measured by venous occlusion
plethysmography, in response to intra-arterial SNP, comparing
alirocumab with statin versus statin alone.
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Study design
This is a single-center, randomized, placebo-controlled study,
which will include healthy low-risk normocholesterolaemic vol-
unteers. It will take place at the National Institute for Health
Research Cambridge Clinical Research Center, Cambridge
University Hospitals NHS Foundation Trust and the overall dur-
ation of the study for each participant will be approximately
10weeks. The study is sponsored by Cambridge University
Hospitals NHS Foundation Trust. The study protocol was
accorded a favorable ethical opinion by the East Midlands –
Leicester South Research Ethics Committee (17/EM/0278) and
was registered on clinicaltrials.gov (N03273972).
The study design is summarized in Figure 1.
All eligible healthy volunteers (for Inclusion/Exclusion cri-
teria see below) will be randomized in a 1:1 ratio to ONE of
the following treatment arms:
Alirocumab treatment arm: Alirocumab 150mg (single sub-
cutaneous injection in clinic) at Visit 2, followed by alirocu-
mab 150mg as single subcutaneous injection in
clinicþ prescription of atorvastatin 20mg (oral tablet) for
14 days once nightly at Visit 3.
OR
Comparator treatment arm: Placebo (single subcutaneous
injection in clinic) in Visit 2, followed by placebo as single
subcutaneous injection in clinicþprescription of atorvastatin
20mg (oral tablet) for 14 days once nightly at Visit 3.
The research team will be blinded as for the administration
of alirocumab or placebo at Visits 2 and 3, while atorvastatin
will be openly prescribed to all study participants at Visit 3.
Study population
The INTENSITY-LOW study will recruit enough healthy
normocholesterolaemic volunteers to ensure that 30 sub-
jects will complete the study (n¼ 15 in each treatment
group). The inclusion/exclusion criteria of the study
population are detailed in Textbox 2. In brief, the study
population will consist of healthy normocholesterolaemic
subjects aged 18–45 years who lack any established CV risk
factors. Study participants would not be eligible for choles-
terol-lowering treatment according to the existing dyslipi-
daemia and CV risk management guidelines. Subjects with
established CV disease or relevant risk factors as well as
subjects who would have any contraindication to any of the
study treatments/procedures will be excluded from
the study.
6. Change in forearm blood flow ratio (additionally absolute and
% change, based on data), as measured by venous occlusion
plethysmography, in response to intra-arterial L-NG-monomethyl
arginine acetate (L-NMMA) infusion, comparing alirocumab
with placebo.
7. Change in forearm blood flow ratio (additionally absolute and
% change, based on data), as measured by venous occlusion
plethysmography, in response to intra-arterial L-NMMA infusion,
comparing alirocumab with statin.
8. Change in forearm blood flow ratio (additionally absolute and
% change, based on data), as measured by venous occlusion
plethysmography, in response to intra-arterial L-NMMA infusion,
comparing alirocumab with statin versus statin alone.
9. Correlation of change in total and LDL-cholesterol to change in
responses to Ach between groups.
10. Change in Augmentation Index (an indicator of arterial stiffness)
between visits and different treatment regimens.
11. Change in aortic Pulse Wave Velocity between visits and
different treatment regimens.
12. Change in carotid intima media thickness (IMT) between visits
and different treatment regimens.
13. Change in lipid profile, high sensitivity C-reactive protein
(hsCRP) and other markers of systemic inflammation between
visits and different treatment regimens.
14. Safety and tolerability parameters, including physical
examination, blood pressure, heart rate, 12-lead
electrocardiograms (ECGs), clinical laboratory tests side effects
and adverse event reporting.
Figure 1. Synopsis of the study design. After a screening visit all eligible volunteers will attend V2 in which they will have pre-dose blood tests and vascular stud-
ies, and then will be randomized to either single sc dose of alirocumab 150mg or placebo. They will then attend V3 14 ± 3 days later to have pre-dose blood tests
and vascular studies and be administered another sc dose of alirocumab 150mg or placebo. After this all participants in both groups (alirocumab and placebo
group) will be prescribed atorvastatin 20mg once nightly for 14 days. They will then attend V4 for post-dose blood tests and vascular studies. A follow up visit (V5)
will take place 7–14 days later. Abbreviations. SC, subcutaneously; V1, Visit 1; V2, Visit 2; V3, Visit 3; V4, Visit 4; V5, Visit 5.
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Textbox 2. INTENSITY-LOW study population – Inclusion and
Exclusion criteria.
Inclusion criteria:
 Apparently healthy male or female individuals
 Age 18-45 years old (inclusive) at screening
 Body weight 45kg and body mass index (BMI) 18.0 - 29.9 kg/m2
 Fasting low density lipoprotein cholesterol (LDL-C) <4.1mmol/l,
triglycerides (TG) <1.7mmol/l and high density lipoprotein (HDL)-
cholesterol 1.0mmol for men and 1.3mmol for women
 Palpable brachial arterial pulse
 Not currently eligible for statin therapy according to current treat-
ment criteria
Exclusion criteria:
The presence of ANY of the following will preclude
participant inclusion:
 History of established cardiovascular disease (coronary heart dis-
ease, cerebrovascular disease, peripheral vascular disease or
abdominal aortic aneurysm)
 Lipid lowering treatment at screening or within 6 weeks
before screening
 Pregnancy at any study visit. Women of childbearing potential will
be included in the study provided that they are not pregnant at
any stage (from screening to the end of the study) and are sexu-
ally abstinent (if this is the preferred lifestyle) or use of highly
effective methods of contraception26
 Ongoing anticoagulation therapy with warfarin or any of the new
oral anticoagulants
 History of hypersensitivity to any of the study drugs/any known
sensitivity to alirocumab or monoclonal antibodies
 History of alcohol or drug abuse or dependence within 6 months
of the study at screening
 Current or previous history of regular smoking (defined as 1 pack-
year) within the last 10 years
 History of hypertension or sustained blood pressure 140/
90mmHg on repeated measurements at screening
 History of type 1 or 2 diabetes or glycated hemoglobin (HbA1c)
48mmol/mol (6.5%) at screening
 Chronic kidney disease defined as an estimated glomerular filtra-
tion rate <60ml/min/1.73m2
 Biological first-degree relatives who have experienced stroke, tran-
sient ischemic attack, myocardial infarction or peripheral vascular
disease (incident event at an age younger than: 55 for male and
65 for female relatives)
 History of autoimmune inflammatory conditions
 Lack of ability to provide informed consent
 Thyroid stimulating hormone > 5.0mU/l at screening
 Clinically significant liver disease based on screening bloods
or history
 History of myositis/rhabdomyolysis
 Any concomitant condition that, at the discretion of the investiga-
tor, may affect the participants’ ability to complete the study or
the study results
Study visits and assessments
Subject recruitment
Potential participants will be identified through a variety of
advertising sources, including recruitment posters, study
websites, newspapers, public areas and social media if
applicable. All subjects will be prescreened for eligibility via
a telephone call (after expressing interest) and will be pro-
vided with a participant information sheet to review for at
least 24 h. The research team will then follow up to assess
whether each subject is interested in taking part. If so, a
screening visit (V1) will be scheduled for the informed con-
sent process to be completed.
Screening visit (visit 1)
Healthy volunteers will attend a screening visit where they
will provide full written informed consent. Following
informed consent, a full eligibility check will be carried out
where the following assessments will be completed: (1) clin-
ical chemistry (as described in the study methods section);
(2) hematology (as described in the study methods section);
(3) pregnancy test (if applicable); (4) 12-lead electrocardio-
gram (ECG); (5) blood pressure and heart rate assessment; (5)
concomitant medication check, (6) physical examination, and
(7) previous medical history. All eligible volunteers will con-
tinue with the next phase of the study.
Visit 2 - Day 1
Visit 2 can be conducted on any day following screening
provided it does not occur >31 days post screening visit. At
Visit 2 the following assessments and procedures will be
completed: (1) clinical chemistry sampling (as described in
the study methods section), (2) haematology (as described in
the study methods section), (3) serum sample for systemic
markers [interleukin (IL)-6, IL-2, matrix metalloproteinase 9
(MMP9) and oxidized low density lipoproteins (oxLDL), (4)
pregnancy test (if applicable), (5) 12-lead ECG; (6) blood pres-
sure and heart rate assessment, (7) arterial stiffness, (8) cen-
tral haemodynamics assessment, (9) carotid intima media
thickness (IMT) measurement, (10) forearm blood flow stud-
ies, (11) concomitant medication check, (12) safety review
and reporting, and, (13) randomization.
Dosing: Following randomization eligible subjects will be
dosed with either alirocumab or placebo in clinic following
completion of the above assessments. Participants will be
assessed for any potential post-dose instant reactions (e.g.
hypersensitivity).
Visit 3 - Pre-dose, bloods and vascular studies -
Day 15± 3days
Approximately 2weeks following Visit 2, participants will be
asked to attend a study visit where the same assessments as
in Visit 2 will be completed. In Visit 3 all subjects will also be
dosed with either alirocumab or placebo in clinic following
completion of the assessments. In addition, participants
randomized to both treatment arms will be prescribed ator-
vastatin 20mg to be taken every evening for 14 days. A pre-
scription will be provided to ensure enough atorvastatin
supply until the next scheduled visit (i.e. 14 days ±3 days).
Following dosing, participants will be assessed for any poten-
tial instant reactions to the subcutaneous alirocumab or pla-
cebo administration (e.g. hypersensitivity).
Visit 4 - Post dose, bloods and vascular studies -
Day 29± 3days
Approximately 2weeks following Visit 3, participants will be
asked to attend a post-dose visit where assessments as in
Visit 2 and Visit 3 will be completed. No dosing will be pro-
vided in this visit and compliance check will be performed
for atorvastatin administration via pill count.
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Visit 5 - Follow up visit - Day 36 to day 43
A telephone follow-up will be scheduled approximately
7–14 days following Visit 4, where a review of any adverse
events (AE)/serious adverse events (SAE) from the last visit
will take place.
Study methods
Clinical assessments
Clinic blood pressure and heart rate will be measured in the
seated position after 5min rest. Repeated blood pressure
(BP) measurements using an automated BP device will be
taken. An average will be used to determine eligibility. A
validated machine will be used.
Non-sterilised, pre-menopausal women will undergo urin-
ary beta-human chorionic gonadotropin (HCG) testing at vis-
its 1–4. They will also be given advice on contraceptive use
in the Participant Information Sheet.
Laboratory assessments
Blood samples will be obtained after 6–8 h overnight fast
for clinical chemistry: Sodium, potassium, glucose, creatinine,
bilirubin [total; direct and indirect will be reported if total is
>2  the upper limit of normal (ULN)], alanine transamin-
ase (ALT), c-glutamyl transferase (cGT), alkaline phosphatase,
urea, total creatine kinase (CK), high sensitivity C-reactive
protein (hsCRP) and serum lipid profile [total cholesterol, tri-
glycerides, high density lipoprotein cholesterol, LDL-C] and
haematology [haemoglobin, haematocrit, platelets, total
white blood cells (WBC), neutrophils, lymphocytes, mono-
cytes, eosinophils and basophils] multiple times throughout
the study. Thyroid stimulating hormone and HbA1c will also
be analyzed at the screening visit. Serum samples will be
collected for storage. A total of 195ml of blood will be
taken from each participant over the course of this study,
which is intended for analysis and/or storage. Blood and
serum samples may be stored for further analysis until study
close. This will be used to analyze systemic markers of
inflammation [for example (but not limited to IL-6, IL-2,
MMP9 etc] and lipid sub-fractions [for example (but not lim-
ited to) oxLDL].
Vascular studies
Arterial stiffness and central haemodynamics
Central haemodynamics as well as arterial stiffness [assessed
by determination of the Augmentation Index (AIx) and the
carotid-to-femoral Pulse Wave Velocity (PWV)] will be deter-
mined using a commercially available SphygmoCor system
(AtCor Medical, Sydney, Australia), as previously described20.
Carotid IMT
Carotid IMT will be measured by using a high-resolution
ultrasound scanner with a 10MHz linear-array transducer
(MyLab25 Gold Ultrasound Machine, Esaote, Italy), with the
volunteer resting in the supine position for at least 5min.
The common carotid artery will be identified and scanned,
2 cm below its bifurcation. Measurements will be repeated 3
times, and the average of the values will be recorded.
Forearm blood flow (FBF) studies
FBF will be measured simultaneously in both arms using
venous occlusion plethysmography with indium-gallium
strain gauges electrically calibrated, as previously described8.
A 27-gauge unmounted steel needle will be inserted into the
non-dominant brachial artery under local anesthesia (1% lig-
nocaine hydrochloride). Saline or drugs will be infused at a
constant rate of 1.0ml/min by means of a constant rate infu-
sion pump. Basal blood flow will be recorded after 20min of
saline infusion. Ach (7.5, 15 and 30 mg/min) will then be
infused intra-arterially at 1ml/min as a measure of endothe-
lial NO activity. Each dose will be infused for 6min and fore-
arm blood flow will be measured for 3min at the end of
each infusion period. After a further 30min washout with
saline, the NO donor, sodium nitroprusside (SNP) will be
infused intra-arterially at 2 doses (3, 10 mg/min) for 6min
each to test for NO-independent mechanisms. Finally, the
NO synthase antagonist L-NG-monomethyl-arginine acetate
(L-NMMA) will be infused after a 30min saline washout,
again at 2 doses (4 and 8mmol/min), and FBF measured as
before. A final 10min of saline will then be infused. BP and
heart rate will be recorded at baseline, and at the end of
each infusion. The ACh, SNP and L-NMMA infusion pattern is
described in Figure 2.
Safety (AE/SAE reporting)
AE/SAEs will be collected and reported from study enroll-
ment towards the follow up visit for all subjects. AE/SAEs
definition and reporting requirement will be consistent with
the current International Conference on Harmonisation/Good
Clinical Practice ICH GCP E6 (R2)21.
Subjects will be withdrawn from the study if ANY of the
withdrawal criteria described in Textbox 3 applies.
Textbox 3. Withdrawal criteria
 Withdrawal of informed consent
 Blood results that determine that the participant is ineligible to
continue further participation in the study
 The investigator determines that continuation of study treatment/
procedures would result in a significant safety risk to the
participant
 If the participant experiences a serious adverse event (SAE), which
would affect their ability to participate in the study (at the discre-
tion of the principal investigator)
 Pregnancy
 Any protocol deviation that results in a significant risk to the par-
ticipants’ safety
 Noncompliance with treatment or procedures
 Lost to follow-up
 Study closed/terminated
 Any other reason, at the discretion of principal investigator
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Statistical analysis
Statistical methods
The primary outcome measure for the intra-arterial infusions
studies will be percentage (%) change in FBF, in response to
intra-arterial Ach infusion, as measured by venous occlusion
plethysmography (infused arm only). Since there is just one
primary outcome, no adjustment for multiplicity will
be made.
Secondary endpoints will additionally include the %
change in FBF (non-infused arm only) and % change in FBF
ratio. Three comparisons for each endpoint will be made:
alirocumab vs placebo, alirocumab vs statin, and alirocu-
mabþ statin vs statin alone. All endpoints will also be ana-
lyzed in relation to Ach, SNP and L-NMMA infusion. BP and
heart rate will also be reported.
For all outcome measures significance of the global treat-
ment effect across the doses will be determined using mixed
effects models. The % change from basal FBF after infusion
with challenge agent at each dose will be the repeated out-
come measure, adjusting for age, sex, baseline (Visit 2) LDL-C
and % change from basal FBF at baseline after infusion with
each dose of challenge agent.
Number of participants to be enrolled
The sample sizing for this physiological study assumes that
the expected effect size is 25% (between alirocumab and
placebo) and the standard deviation of outcome variable is
0.23. To achieve 80% power to detect this difference with a
significance level of 5% it is estimated that 13 subjects per
group would be required22. With a withdrawal/non-evaluable
subject rate of 10% a total of 15 per group subjects will be
recruited leading to a total required sample size of
30 subjects.
Discussion
The main objective of the INTENSITY-LOW study is to under-
stand whether lowering LDL-C, within the currently accepted
normal range, has the potential to reduce CV risk in low-risk
healthy individuals. A mechanistic explanation of this benefit
might also be provided through an improvement in endo-
thelial function and a reduction in systemic inflammation. In
this context, the physiological effects of both alirocumab and
atorvastatin on NO bioavailability (as measured by forearm
plethysmography) as well as on markers of systemic inflam-
mation will be assessed.
It has widely been shown in clinical trials that ‘pushing’
on-treatment LDL-C to lower levels is linearly associated with
improved CV morbidity and mortality2. This was particularly
apparent in secondary prevention studies, in which adding
PCSK9 inhibitors to intensive statin treatment ± ezetimibe
achieved much lower LDL-C levels than statins ±
ezetimibe13–15. Prior to the introduction of PCSK9 inhibitors,
the lowest on-treatment LDL-C to further reduce CV morbid-
ity and mortality in secondary prevention had been
1.4mmol/l. This level was achieved by simvastatin
40mgþ ezetimibe 10mg daily13.
The FOURIER (Evolocumab and clinical outcomes in
patients with cardiovascular disease) study included 27,564
patients with established atherosclerotic CV disease and
baseline LDL-C levels 1.8mmol/l, while on high-intensity
statins ± ezetimibe. These patients were randomized to either
subcutaneous evolocumab (140mg every 14 days or 420mg
monthly) or placebo. The median baseline LDL-C of the study
participants was 2.4mmol/l. Evolocumab treatment resulted
in an LDL-C reduction to 0.78mmol/l at 48weeks. This reduc-
tion was associated with a significantly lower by 15% risk for
the composite primary endpoint of CV death, myocardial
infarction, stroke, unstable angina or revascularisation com-
pared with placebo14.
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Figure 2. Ach, SNP and L-NMMA infusion pattern in FBF studies. FBF will be measured at baseline and after 20 mins of saline intra-arterial infusion at a rate 1ml/
min. Following this, 3 different concentrations of Ach will be infused intra-arterially at the same rate for 6 mins each. At the last 3 mins of each infusion period FBF
will be measured. After 30 mins of washout 2 different concentrations of SNP will be infused intra-arterially for 6 mins each, and FBF will be measured again at the
last 3 mins of each infusion period. Following 30 mins washout period 2 different concentrations of L-NMMA will be infused intra-arterially for 6 mins each, and
FBF will be measured again at the last 3 mins of each infusion period. A final 10min of saline will then be infused. BP and heart rate will be recorded at baseline,
and at the end of each infusion. 1Blood pressure and heart rate recorded at baseline and at the end of each infusion. 2Basal FBF recorded after 20-min Saline infu-
sion. 3Forearm blood flow recorded after each dose of challenge agent for 3 min. Abbreviations. Ach, acetylcholine; SNP, sodium nitroprusside; L-NMMA,
L-NG-monomethyl-arginine acetate; FBF, forearm blood flow.
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More recently, the ODYSSEY OUTCOMES (Alirocumab and
cardiovascular outcomes after acute coronary syndrome)
study included 18,924 patients, who had experienced an
acute coronary syndrome up to 12months earlier. Those sub-
jects had LDL-C 1.8mmol/l while on high-intensity or max-
imum tolerated statins. Study participants were randomized
to either alirocumab 75mg (titrated to LDL-C 0.6–1.3mmol/l)
or placebo every 2weeks. Alirocumab resulted in a signifi-
cant LDL-C reduction from a baseline 2.38mmol/(median) to
0.98, 1.1 and 1.4mmol/l (median) at months 4, 12 and 48,
respectively. The composite of coronary death, non-fatal
myocardial infarction, stroke (fatal or non-fatal) or unstable
angina requiring hospitalization was the primary endpoint.
After 2.8 years (median) these changes were associated with
a 15% reduced risk (p< .001) of this endpoint. Likewise, they
were related to a 15% further reduction in overall mortality.
Interestingly, this benefit was more prominent among
patients with baseline LDL-C> 2.6mmol/l, while also signifi-
cant for those with LDL-C< 2.07mmol/l15.
Due to the lack of outcome trials with PCSK9 inhibitors it
is unclear whether aggressively reducing LDL-C to very low
levels is beneficial on CV outcomes in primary prevention.
The ASCOT-LLA (Anglo-Scandinavian Clinical Outcomes Trial -
Lipid Lowering Arm) included 10,305 high-risk hypertensive
patients with at least 3 other CV risk factors, and a baseline
non-fasting total cholesterol 6.5mmol/l. These were
randomized to either atorvastatin 10mg daily or placebo.
LDL-C was reduced from a mean baseline 3.4mmol/l to
2.3mmol/l at the end of follow up in 3.3 years (median).
These changes were associated with a 36% reduced risk of
the primary endpoint of fatal coronary heart disease or non-
fatal myocardial infarction23.
The JUPITER (Rosuvastatin to prevent vascular events in
men and women with elevated C-reactive protein) study
assessed the potential benefits of lowering LDL-C in appar-
ently healthy normocholesterolaemic individuals (LDL-
C< 3.4mmol/l) with a raised hsCRP 2.0mg/l. It included
17,802 participants who were randomized to rosuvastatin
20mg daily or placebo. The lowest on-treatment LDL-C levels
achieved by rosuvastatin was 1.4mmol/l at 48months. In this
study, rosuvastatin was associated with a 44% reduced risk
of the composite endpoint of myocardial infarction, stroke,
revascularisation, hospitalization for unstable angina or
CV death19.
However, despite the relatively low or normal baseline
cholesterol in ASCOT-LLA and JUPITER, all or most participants
were at intermediate or high CV risk18,19. Thus, the evidence
of potential benefits for effective LDL-C lowering in low-risk
hypercholesterolaemic subjects is very poor. There is an even
greater paucity of data in normocholesterolaemic subjects.
The INTENSITY-LOW study will include low-risk normocho-
lesterolaemic individuals lacking any of the established CV
risk factors or predictors. Therefore, neither treatment inter-
vention is intended for therapeutic benefit, since study par-
ticipants would not be eligible for lipid lowering treatment
according to the current guidelines for the management of
dyslipidaemia and CV risk. In this context, results from the
INTENSITY-LOW study may provide evidence for or against
the concept that there is still a relevant cholesterol-related
CV risk in low-risk individuals. This issue has not been
addressed by the current management guidelines.
We have utilized a PCSK9 inhibitor (i.e. alirocumab) as our
choice of a non-statin lipid-lowering treatment to achieve
similar levels of LDL-C lowering as atorvastatin. The doses
were based on previous evidence showing that single-dose
alirocumab 150mg at steady state is expected to reduce
LDL-C by approximately 40% in healthy normocholesterolae-
mic individuals24, 25, akin to atorvastatin 20mg daily. We
assume three different on treatment LDL-C levels according
to the current design: one after alirocumab single dose at
Visit 3, one after placebo at Visit 3 and one after alirocu-
mabþ atorvastatin at Visit 4.
Placeboþ atorvastatin at Visit 4 is expected to achieve
similar LDL-C levels to alirocumab single dose at Visit 3.
Comparing the differential effects of these regimens on
endothelial function, inflammation and arterial stiffness at
these timepoints will allow the assessment of differential
effects of statin vs non-statin treatment on vascular function
for similar LDL-C reduction. A lack of significant difference
between treatment arms will suggest that vascular effects of
the regimens are LDL-C-dependent only and disprove the
theory of statin-related pleiotropic effects.
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